Found: 14
Select item for more details and to access through your institution.
Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma.
- Published in:
- Journal of Immunotherapy & Precision Oncology, 2024, v. 7, n. 1, p. 67, doi. 10.36401/JIPO-23-19
- By:
- Publication type:
- Article
Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: A meta-analysis.
- Published in:
- Asia Pacific Journal of Clinical Oncology, 2014, v. 10, n. 3, p. 273, doi. 10.1111/ajco.12231
- By:
- Publication type:
- Article
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 4, p. 747, doi. 10.1007/s10637-022-01237-3
- By:
- Publication type:
- Article
Symptomatic brain metastases in melanoma.
- Published in:
- Experimental Dermatology, 2024, v. 33, n. 4, p. 1, doi. 10.1111/exd.15075
- By:
- Publication type:
- Article
The kinase polypharmacology landscape of clinical PARP inhibitors.
- Published in:
- Scientific Reports, 2020, v. 10, n. 1, p. 1, doi. 10.1038/s41598-020-59074-4
- By:
- Publication type:
- Article
Computational repurposing of oncology drugs through off‐target drug binding interactions from pharmacological databases.
- Published in:
- Clinical & Translational Medicine, 2024, v. 14, n. 4, p. 1, doi. 10.1002/ctm2.1657
- By:
- Publication type:
- Article
Dramatic clinical response in the treatment of small cell glioblastoma multiforme.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2022, v. 47, n. 6, p. 832, doi. 10.1111/jcpt.13608
- By:
- Publication type:
- Article
Combination of BRAF and MEK inhibition in BRAF V600E mutant low‐grade ganglioglioma.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2020, v. 45, n. 5, p. 1172, doi. 10.1111/jcpt.13112
- By:
- Publication type:
- Article
ACTR-55. TUMOR VOLUME AS A PREDICTOR OF RESPONSE TO ANTI-EGFR ADC ABT-414.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi24, doi. 10.1093/neuonc/noy148.087
- By:
- Publication type:
- Article
EPID-13. ANTI-ANGIOGENIC THERAPY FOR HIGH-GRADE GLIOMA: A META-ANALYSIS.
- Published in:
- Neuro-Oncology, 2018, v. 20, p. vi82, doi. 10.1093/neuonc/noy148.340
- By:
- Publication type:
- Article
Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
- Published in:
- Clinical Medicine Insights: Oncology, 2018, n. 12, p. 1, doi. 10.1177/1179554918759079
- By:
- Publication type:
- Article
PD-L1 and Tumor Infiltrating Lymphocytes as Prognostic Markers in Resected NSCLC.
- Published in:
- PLoS ONE, 2016, v. 11, n. 4, p. 1, doi. 10.1371/journal.pone.0153954
- By:
- Publication type:
- Article
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
- Published in:
- 2020
- By:
- Publication type:
- journal article
A systematic review of the impact of brain tumours on risk of motor vehicle crashes.
- Published in:
- Journal of Neuro-Oncology, 2024, v. 166, n. 3, p. 395, doi. 10.1007/s11060-024-04586-6
- By:
- Publication type:
- Article